In an interview, Andrew Kuykendall, MD, discussed fedratinib’s potential as an effective option for patients with ...

During a Community Case Forum event in partnership with the Medical Oncology Association of Southern California, Edward S.

A panelist discusses how, despite recent advances in relapsed/refractory follicular lymphoma treatment, important unmet needs ...

A study by UVA Health found that while ChatGPT Plus holds potential for enhancing diagnoses, physicians need better training ...

Ticiana Leal, MD, discussed the case of a 73-Year-Old woman with progressive extensive-stage small cell lung cancer.

In separate, live virtual events, Vincent K. Lam, MD, and Chul Kim, MD, MPH, discuss molecular assays and treatment options ...

During a Case-Based Roundtable event, Laura Huppert, MD, reviewed antibody-drug conjugates for a patient with metastatic ...

SGX301 has led positive results in early-stage CTCL, with over 70% achieving treatment success in the phase 3 FLASH study.

Panelists discuss how the CEPHEUS trial demonstrates the comparative efficacy and safety of subcutaneous daratumumab combined with VRd vs VRd alone in patients with transplant-ineligible or transplant ...

Experts examine the potential role of chimeric antigen receptor (CAR) T-cell therapy in chronic lymphocytic leukemia ...

Virginia G. Kaklamani, MD, DSc, discusses findings from the phase 3 TROPION-Breast01 trial of datopotamab deruxtecan.

LOAd703, an oncolytic adenovirus with transgenes for 4-1BBL and TMZ-CD40L, has received FDA fast track designation for ...